Competition and Price Cuts Slow Strong IO Momentum In China

While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities. 

Chinese biotechs posted slower growths in sales of PD-1 agents.
Chinese biotechs posted slower growths in 3Q sales of PD-1 agents. • Source: Alamy

More from China

More from Focus On Asia